STOCK TITAN

Ernexa Therapeutics adds $5K a month in CFO cash pay

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Ernexa Therapeutics Inc. (ERNA) approved an addendum to Mark J. Keeley’s consulting agreement for his Chief Financial Officer services, effective November 9, 2026. The addendum adds $5,000 in monthly cash compensation to his current share-based compensation. Payment is due on the last day of each month and is prorated for November 2026.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Monthly cash compensation $5,000 per month Added to Mark J. Keeley's current share-based compensation under his consulting agreement
share-based compensation financial
"current share-based compensation under the Consulting Agreement"
Share-based compensation is when a company pays employees, executives or directors with its own stock or rights to buy stock instead of, or in addition to, cash. Think of it like receiving store gift cards instead of extra paycheck — it can motivate staff to boost the company’s value, but it also increases the number of shares outstanding and can shrink each existing owner’s slice of profits and voting power. Investors watch it because it affects reported earnings, share count and the alignment between management and shareholders.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much cash compensation will Mark J. Keeley receive as Ernexa (ERNA) CFO?

Mark J. Keeley, who provides Chief Financial Officer services, will receive $5,000 in monthly cash compensation, supplementing his current share-based compensation.

When does Ernexa's addendum for Mark J. Keeley take effect, and when is payment due?

The addendum is effective November 9, 2026; monthly payments are due on the last day of each month, with the November 2026 payment prorated.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0000748592 0000748592 2026-11-14 2026-11-14 0000748592 ERNA:CommonStockParValue0.005PerShareMember 2026-11-14 2026-11-14 0000748592 ERNA:CommonStockPurchaseWarrantsMember 2026-11-14 2026-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 14, 2026

 

Ernexa Therapeutics Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-11460   31-1103425

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

1035 Cambridge Street, Suite 18A    
Cambridge, MA   02141
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (617) 798-6700

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol   Name of each exchange on which registered
Common Stock, par value $0.005 per share   ERNA   The Nasdaq Stock Market LLC
Common Stock Purchase Warrants   ERNAW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 14, 2026, the Board of Directors (the “Board”) of Ernexa Therapeutics Inc., a Delaware corporation (the “Company”), upon the recommendation of the Compensation Committee of the Board, approved a Consulting Agreement Addendum, effective November 9, 2026 (the “Addendum”), to the Consulting Agreement, dated August 10, 2026 (the “Consulting Agreement”), by and between the Company and Mark J. Keeley, pursuant to which Mr. Keeley provides Chief Financial Officer services to the Company.

 

Pursuant to the Addendum, Mr. Keeley’s current share-based compensation under the Consulting Agreement is supplemented with monthly cash compensation in the amount of $5,000, payable on the last day of each month and prorated for the month of November 2026. All other terms of the Consulting Agreement remain in full force and effect.

 

The foregoing description of the Addendum does not purport to be complete and is qualified in its entirety by reference to the full text of the Addendum, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit

Number

  Description
10.1   Consulting Agreement Addendum, effective November 9, 2026, by and between Ernexa Therapeutics Inc. and Mark J. Keeley.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  Ernexa Therapeutics Inc.
   
Dated: November 19, 2026 By: /s/ Sanjeev Luther
    Sanjeev Luther
    President and Chief Executive Officer

 

 

Filing Exhibits & Attachments

5 documents

Keep reading